Barcelona, Spain– INBRAIN Neuroelectronics, a clinical-stage company developing next-generation brain-computer interfaces (BCIs), has been named a 2025 Technology Pioneer by the World Economic Forum. The honor recognizes INBRAIN’s work at the forefront of neurotechnology, particularly its use of graphene to create intelligent, precision therapies for neurological conditions.
Founded in 2020, INBRAIN is developing a new class of neuroelectronic implants that are ultra-thin, minimally invasive, and capable of real-time brain signal decoding and modulation. The platform, powered by graphene—a highly conductive and biocompatible material—aims to deliver adaptive and personalized treatments for conditions such as epilepsy, Parkinson’s disease, and stroke-related impairments. The company’s approach integrates neural data with intelligent computing to enable autonomous therapeutic interventions tailored to individual patient needs.
Carolina Aguilar, Ph.D., Co-Founder and CEO of INBRAIN, said the World Economic Forum’s recognition underscores the company’s mission to redefine the standard of care for neurological disorders. “Being named a Technology Pioneer validates our commitment to precision neuromodulation and outcome-based treatment,” she said. “It highlights the transformative potential of combining biology with advanced neurotechnology.”
The World Economic Forum’s Technology Pioneer program annually selects a limited number of early-stage companies from across the globe that are poised to shape the future of their industries. Past recipients have included influential players in biotech, artificial intelligence, and digital health. As part of the 2025 cohort, INBRAIN will join policy discussions and strategic forums, including the Annual Meeting of the New Champions in Tianjin, China, and a dedicated gathering in New York later this year.
The announcement follows a €4 million grant awarded to INBRAIN by Spain’s Ministry of Industry and Tourism under the PERTE Chip initiative. The funding will support the further development of INBRAIN’s BCI platform, accelerating efforts to bring precision neural modulation to clinical practice.
With its proprietary technology and growing international recognition, INBRAIN is positioning itself as a leader in the emerging field of intelligent neuroelectronic therapeutics.
